One key function of LC3 is to facilitate the delivery of autophagosomal membranes to lysosomes[@R6]. Intriguingly, most LC3-decorated hepatic parasites seem to escape this fate[@R3],[@R4]. This implies that *Plasmodium* exo-erythrocytic forms (EEFs) actively disrupt the autophagic flux to avoid the deleterious effects of fusing the vacuole with lysosomes. The PVM is ideally positioned to carry out this task and several genetic studies point to the critical contribution of PVM resident proteins to parasite survival[@R5],[@R7],[@R8]. Nevertheless, a putative autophagy subversion activity in *Plasmodium* has yet to be discovered. Of the few PVM proteins identified thus far, UIS3 has the greatest impact on *Plasmodium* survival inside host hepatocytes[@R5],[@R9]. Parasites lacking UIS3 (*uis3(-)*) infect host cells, but disappear rapidly thereafter and fail to complete development[@R5]. To determine whether UIS3 influences *Plasmodium*'s susceptibility to host autophagy, we allowed *uis3(+)* and *uis3(-) P. berghei* parasites to infect HepG2 cells that had been depleted of Atg5 or Rab7 to arrest the autophagic flux in early (LC3 membrane conjugation) and late (lysosomal fusion) stages, respectively[@R10],[@R11] ([Fig. 1a](#F1){ref-type="fig"}, [Supplementary Fig.1 a, b](#SD2){ref-type="supplementary-material"}). Consistent with previous reports[@R5], *uis3(-)* parasites were virtually undetectable in control HepG2 cells and the few hepatic schizonts observed 65 h after infection did not express MSP1, the merozoite surface marker seen in fully mature *uis3(+)* parasites ([Fig. 1b, c](#F1){ref-type="fig"}, [Supplementary Fig. 1c](#SD2){ref-type="supplementary-material"}). Strikingly, depletion of Atg5 or Rab7 in HepG2 cells was sufficient to fully revert the phenotype of *uis3(-)* mutants to a wild-type one ([Fig. 1b, c](#F1){ref-type="fig"}, [Supplementary Fig. 1c](#SD2){ref-type="supplementary-material"}). With the autophagy flux of the host cell arrested, *uis3(-)* parasites behaved as their *uis3(+)* counterparts with respect to schizont abundance as well as MSP1 expression ([Fig. 1b, c](#F1){ref-type="fig"}, [Supplementary Fig. 1c](#SD2){ref-type="supplementary-material"}). Parasites that complete the liver stage successfully induce the release of blood-infective merozoite-filled sacs (merosomes) from infected cells[@R12]. To test the viability of the *uis3(-)* progeny released by HepG2-infected cells, we harvested the cell culture supernatants (HepG2 SN) 65 h after infection, inoculated them into mice, and monitored the onset of blood-stage infection by collecting blood samples daily ([Fig. 1a](#F1){ref-type="fig"}). HepG2 SN from Atg5 or Rab7-depleted cells infected with *uis3(-)* mutants caused patent blood-stage infections within 4 to 5 days of mice inoculation, similar to mice inoculated with HepG2 SN derived from *uis3(+)*-infected cells ([Fig. 1d-f](#F1){ref-type="fig"}). In stark contrast, HepG2 SN collected from control *uis3(-)* infected cells did not cause infection in mice ([Fig. 1d-f](#F1){ref-type="fig"}). Thus, loss of autophagy during the liver stage fully restores *uis3(-)* infectivity. Additionally, the survival rates of *uis3(-)* and *uis3(+)* parasites in Atg3, Atg5, or Atg7 knockout mouse embryonic fibroblasts (MEFs) were also identical, whereas few *uis3(-)* mutants survived in wild-type MEFs ([Fig. 1g](#F1){ref-type="fig"}). To obtain additional evidence that *uis3(-)* parasites are removed by host autophagy, newly invaded hepatoma cells were treated with chloroquine (CQ), a lysosomotropic alkalizing agent that impairs the lysosomal degradation of autophagic cargo. CQ treatment, like genetic impairment of autophagy, rescued *uis3(-)* mutants ([Fig. 1h](#F1){ref-type="fig"}). On rare occasions, we were able to observe *uis3(-)* parasites that exhibited distinctive signs of having undergone fusion with LAMP1-positive lysosomes, most prominently, the presence of LAMP1 within the vacuole and loss of the PVM marker, UIS4 ([Supplementary Fig. 1 d](#SD2){ref-type="supplementary-material"}). Thus, we conclude that *uis3(-)* mutants normally fail to establish liver stage infections because they are promptly eliminated by host autophagy and that the critical function of UIS3 is to protect *Plasmodium* from this innate defense mechanism.

Next, we aimed to elucidate how UIS3 interferes with host autophagy. To that end, we complemented *uis3(-)* parasites with the UIS3 gene fused C-terminally to c-Myc (this parasite line will be referred to as *uis3-myc*) ([Supplementary Fig. 2](#SD2){ref-type="supplementary-material"}). Immunofluorescence analysis of liver stage schizonts, revealed that UIS3-myc co-localised with host LC3 and UIS4 to the PVM ([Fig. 2a, b](#F2){ref-type="fig"}, [Supplementary Fig. 3a, b](#SD2){ref-type="supplementary-material"}). Of note, immuno-electron microscopy showed LC3 in direct association with the PVM, with no evidence of autophagosomal double membranes -- a hallmark of canonical autophagy -- forming around the PV ([Fig. 2c](#F2){ref-type="fig"}). Prompted by these observations, we asked whether UIS3 might form a molecular complex with LC3. We allowed *uis3-myc* parasites to infect HeLa cells stably expressing GFP-LC3 and, 24 h after infection, proceeded to immunoprecipitate UIS3-myc. Strikingly, GFP-LC3 was found to co-immunoprecipitate with UIS3 ([Fig. 2d](#F2){ref-type="fig"}). We further confirmed this association in *P. berghei* infected mouse primary hepatocytes ([Supplementary Fig. 3c](#SD2){ref-type="supplementary-material"}), thus ruling out the possibility of a potential artefact linked to GFP-LC3 over-expression. LC3 immunoprecipitation could not be detected in cells infected with *uis3(-)* mutants, which do not express UIS3 ([Fig. 2d](#F2){ref-type="fig"}, [Supplementary Fig. 3c](#SD2){ref-type="supplementary-material"}). Next, we used recombinant UIS3 and LC3 to test whether the two proteins directly associate. Full-length UIS3 comprises a signal peptide, a short intravacuolar N-terminal domain, a transmembrane anchor, and a C-terminal domain that spans residues 83 to 229 and is predicted to be exposed to the host cytosol. Previous studies reported that the C-terminal domain of *P. falciparum* UIS3 is prone to dimerisation, but undergoes proteolytic cleavage in solution yielding a stable and soluble monomeric fragment consisting of residues 130 to 229 (hereafter referred to as soluble UIS3, s*Pf*UIS3)[@R13]. Using recombinant GST-LC3, we were able to pull down recombinant His-tagged s*Pf*UIS3 ([Fig. 2e](#F2){ref-type="fig"}). The dissociation constant (*K*~D~) for the complex measured by surface plasmon resonance was of 0.244 μM ([Fig. 2f, g](#F2){ref-type="fig"}). Despite being co-localised with both UIS3 and UIS4 on the PVM, LC3 was shown to co-immunoprecipitate with s*Pb*UIS3, but not with the corresponding C-terminal domain of *Pb*UIS4 ([Supplementary Fig. 3d](#SD2){ref-type="supplementary-material"}). We also did not observe co-immunoprecipitation of L-FABP with recombinant s*Pf*UIS3 ([Supplementary Fig. 3e](#SD2){ref-type="supplementary-material"}), in line with previous work suggesting that the reported interaction between the C-terminus of *P. yoelii* UIS3 and mouse L-FAPB[@R14] might be species specific[@R15]. Collectively, these data demonstrate that the distal C-terminal subdomain of UIS3, spanning amino acids 130-229, binds to LC3 directly. While our data establish that UIS3 forms a molecular complex with LC3, the association of LC3 with the PVM was found to be host-driven -- two core components of the LC3 conjugation system, Atg3 and Atg5, were shown to be essential -- and independent of UIS3 ([Supplementary Fig. 4a-d](#SD2){ref-type="supplementary-material"}). In contrast, neither ULK1, the AMPK-regulated autophagy-initiating kinase, nor the autophagy receptors p62 and NDP52, all previously implicated in xenophagy[@R16], were required ([Supplementary Fig. 4e-g](#SD2){ref-type="supplementary-material"}). This is consistent with recent reports highlighting the role of Atg5 and the lack of involvement of the autophagy-initiation complex in targeting LC3 to the PVM[@R3],[@R17]. LC3 association with the PVM was also unaffected by ROS scavengers ([Supplementary Fig. 4h, i](#SD2){ref-type="supplementary-material"}), implying that the host response against *Plasmodium* is mechanistically unrelated to LC3-associated phagocytosis (LAP). LAP has been described as a microbicidal pathway wherein elements of the LC3 conjugation system transfer LC3 in a ROS-dependent manner to pathogen-containing phagosomes[@R18]**.** Intriguingly, the pathway leading to *Plasmodium* targeting by autophagy appears to be inhibited by ULK1. Indeed, we observed significantly higher levels of PVM-associated LC3 upon knockdown of ULK1 expression ([Supplementary Fig. 4f](#SD2){ref-type="supplementary-material"}). These results confirm the unconventional nature of the host autophagy response against *Plasmodium* and imply that the association of LC3 to the PVM precedes the UIS3-LC3 interaction.

Whereas LC3 binding partners typically contain an LC3-Interacting Region (LIR) with the consensus sequence W/F-x-x-I/L/V[@R19],[@R20], UIS3 lacks this canonical LIR ([Supplementary Fig. 5a](#SD2){ref-type="supplementary-material"}). To gain further insight on the specific mode of binding of UIS3 to LC3, we modelled the three-dimensional structure of the putative complex between s*Pf*UIS3 or s*Pb*UIS3 and LC3 using a molecular docking algorithm and the published X-ray structures of s*Pf*UIS3[@R13] and LC3B[@R21] ([Fig. 3a-d](#F3){ref-type="fig"}, and [Supplementary Fig. 5](#SD2){ref-type="supplementary-material"}). Our *in silico* analysis predicted that the interaction is likely to be driven by a flexible turn between helices α2 and α3 of UIS3 (N181, M182, and E183 in *P. falciparum* UIS3) and the β2 strand of LC3 ([Fig. 3a, b](#F3){ref-type="fig"}). The complex appears to be additionally stabilised by polar interactions involving K213 and Q217 ([Fig. 3b](#F3){ref-type="fig"}). In the *P. berghei* complex, the residues located in equivalent positions are D173, Y174, and D175, with E205 and K209 stabilising the complex through electrostatic interactions ([Fig. 3c, d](#F3){ref-type="fig"}). In order to validate these predictions, we substituted the above amino acids for alanine to measure the effect of the substitutions on UIS3 binding to LC3. Simultaneous or individual mutations on all five residues abolished the interaction of s*Pf*UIS3 with LC3 ([Fig. 3e, g](#F3){ref-type="fig"}). Likewise, alanine substitutions of the equivalent positions in s*Pb*UIS3 abrogated binding to LC3 almost completely ([Fig. 3f](#F3){ref-type="fig"}). Of note, the circular dichroism (CD) spectra of recombinant s*Pf*UIS3 proteins harboring the above mutations did not reveal any significant effect of the amino acid substitutions on protein conformation ([Fig. 3h](#F3){ref-type="fig"}). Detailed analysis of the predicted LC3-UIS3 complexes from *P. berghei* and *P. falciparum* ([Fig. 3a-d](#F3){ref-type="fig"}, [Supplementary Fig. 5d, e](#SD2){ref-type="supplementary-material"}) indicated that the LC3 surface where UIS3 putatively binds coincides with the surface recognised by autophagy proteins containing canonical LIR motifs, such as p62[@R19],[@R20],[@R22]. Mutations of key residues in this LIR-binding LC3 surface to alanine abolished the interaction between s*Pf*UIS3 and LC3 ([Fig. 3i](#F3){ref-type="fig"}), as predicted. Thus, although UIS3 lacks a canonical LIR, our data demonstrate that the LIR-binding surface of LC3 can accommodate this atypical interaction.

Since UIS3 and canonical LIR motifs interact with the same region of LC3, we next hypothesised that UIS3 might interfere with the binding of LIR-containing proteins to LC3, thus interrupting the autophagic flux. To examine whether the UIS3-LC3 interaction represents a physiological autophagy subversion mechanism, we quantified the impact of heterologous UIS3 expression on the autophagic flux of HeLa cells. As a readout for autophagy, we monitored p62 degradation in response to amino acid starvation[@R23],[@R24]. Strikingly, s*Pb*UIS3^WT^ inhibited the degradation of p62 induced by amino acid depletion, whereas UIS3 mutants had no effect ([Fig. 4a, b](#F4){ref-type="fig"}). The data demonstrates that binding of UIS3 to LC3 disrupts the autophagic flux, hinting at the possibility that UIS3 functions as an autophagy inhibitor, through a hindrance effect on the LC3 surface. To explore this hypothesis, we setup a LUMIER-based competition assay[@R25] in which s*Pf*UIS3 or p62 were complexed to GST-LC3 and subsequently incubated with increasing concentrations of the p62 LIR[@R22] ([Fig. 4c](#F4){ref-type="fig"}). We found that higher concentrations of p62 LIR were necessary to disrupt the UIS3-LC3 complex compared to p62-LC3 ([Fig. 4d](#F4){ref-type="fig"}). This is consistent with the lower *K*~D~ measured for the UIS3-LC3 interaction ([Fig. 2g](#F2){ref-type="fig"}) compared to similar measurements for canonical LIR sequences[@R26]. To determine how pervasive the UIS3 hindrance effect was, we examined the impact of s*Pf*UIS3 on the association between the LIR-containing Rab7 effector, PLEKHM1[@R27], and recombinant GST-LC3. When s*Pf*UIS3^WT^ and PLEKHM1 were co-expressed, LC3 pulldowns were significantly depleted of PLEKHM1 and enriched in UIS3, whereas mutations that reduced the affinity of UIS3 for LC3 restored the PLEKHM1-LC3 association ([Fig. 4e](#F4){ref-type="fig"}). Taken together, these observations not only demonstrate that *Plasmodium* UIS3 antagonizes LIR-mediated LC3 interactions by binding to a conserved LIR-interacting surface on LC3, but they also confirm UIS3 as a *bona fide* autophagy inhibitor.

In this study, we show that *Plasmodium* parasites escape autophagy by engaging host LC3 in an inhibitory interaction with the cytosolic domain of the PVM transmembrane protein UIS3. Our observations demonstrate that UIS3 competitively inhibits the binding of LIR-containing host proteins to the LIR-docking surface of LC3. This strongly suggests that the UIS3-mediated protection against antiplasmodial autophagy is a direct consequence of LC3 being sequestered into UIS3-LC3 complexes on the PVM ([Fig. 4f](#F4){ref-type="fig"}, [Supplementary Fig. 6](#SD2){ref-type="supplementary-material"}). Although UIS3 is necessary to avert the potential deleterious effects of the association of LC3 to the PVM, whether *Plasmodium* succeeds in evading autophagy probably depends on how much of the PVM-associated LC3 is bound by UIS3. This, in turn, is determined by the levels of UIS3 expression and the robustness of the antiplasmodial response, both of which may diverge significantly between individual parasites and hosts, and could explain the observed vulnerability of *P. berghei* parasites to autophagy in previous reports[@R3],[@R4].

Evidence that IFN-γ enhances LC3 recruitment onto the PVM of *P. vivax*, causing parasite elimination[@R28], supports the idea that host autophagy may be chemically enhanced to suppress the protective effect of UIS3 expression. Repurposing autophagy-inducing drugs for malaria prophylaxis might thus be a safe and cost-effective way of breaking the transmission cycle in endemic areas. Whether clinically available autophagy inducers activate the non-canonical autophagy pathway targeting *Plasmodium* in hepatic cells remains to be determined. Of note, neither metformin nor rapamycin, two of the best-known autophagy-inducing drugs, affect the number of infected cells *in vitro* or *in vivo*[@R3],[@R8],[@R29], supporting our observations that antiplasmodial autophagy is mechanistically distinct from the AMPK- and mTOR-regulated canonical autophagy pathway.

Recent reports underscored the risk of breakthrough infections in mice immunised with a *uis3(-) P. berghei* ANKA whole-organism vaccine[@R30]. The data presented here suggest that host genetic or metabolic factors compromising the autophagy response might be the cause of such breakthrough infections. Although insufficiently safe on its own, UIS3 deletion is likely to improve the safety of any genetically-attenuated whole-organism vaccine against malaria by enhancing the susceptibility of hepatic parasites to host autophagy. Additionally, with the spread of drug resistance casting a shadow over malaria eradication efforts, the protein-protein interaction between UIS3 and LC3 constitutes a promising new target for tailored pharmacological interventions aiming at controlling *Plasmodium* liver infection and disease.

Methods {#S1}
=======

Chemicals {#S2}
---------

RPMI 1640, DMEM, EBSS, and other cell culture reagents were purchased from Gibco Invitrogen. All chemicals were from Sigma-Aldrich, except specified otherwise. Lipofectamine (Invitrogen) was used for transfection of HepG2 cells. siRNAs were transfected using Lipofectamine RNAiMAX in OptiMEM (Invitrogen).

Cell Lines {#S3}
----------

Huh7, HepG2, and HEK 293T (ATCC) cells were cultured under standard conditions in RPMI 1640 (Huh7) or DMEM (HepG2 and HEK 293T) medium supplemented with 10% FCS, 1% non-essential aminoacids (RPMI 1640), 1% glutamine, 1% penicillin/streptomycin, and 1% Hepes. Mouse embryonic fibroblasts (MEFs) were obtained from the Riken BioResource Center (*Atg5^+/+^* (RCB2710) and *Atg5^-/-^* (RCB2711)[@R31]; M. Komatsu, Tokyo Metropolitan Institute of Medical Science (*Atg3^+/+^* and *Atg3^-/-^*)[@R32], and T. Finkel, NIH National Heart, Lung, and Blood Institute (*Atg7^+/+^* and *Atg7^-/-^*)[@R33]. HeLa cells expressing GFP-LC3 were a kind gift from T. Hyman, MPI-CBG. MEFs and HeLa cells were maintained in DMEM supplemented as before. MEFs were validated through qRT-PCR and HeLa cells were tested for the expression of GFP-LC3 by Western blot. All cell lines were routinely tested for mycoplasma contamination.

Mice {#S4}
----

All mice used in this study were C57BL/6J males, between 6 to 8 weeks of age, housed in the animal facility of the Instituto de Medicina Molecular in Lisbon. All protocols were approved by the internal animal care committee of the Instituto de Medicina Molecular and were performed according to national and European regulations.

Mouse primary hepatocytes {#S5}
-------------------------

Mouse primary hepatocytes were isolated using a modified two-step perfusion protocol followed by a Percoll purification step[@R34],[@R35]. Briefly, mice were sacrificed by CO2 inhalation and immediately processed for cannulation of the portal vein using a 26-gauge needle. Next, the inferior vena cava (IVC) was cut to allow fluid to drain. Liver perfusion medium (LPM) was perfused at 8--9 mL/min for 10 min, followed by liver digestion medium (LDM) also at a rate of 8--9 mL/min for 10 min. Intermittent clamping of the IVC (3-s clamp every 30 s) was performed during LDM perfusion to improve tissue digestion. After digestion, the liver was excised and the cells were liberated by tearing and shaking of the liver with forceps. The cell suspension was then sequentially filtered through a 100-μm and a 70-μm cell strainer and spun at 50g for 3 min. The cell pellet was resuspended in Williams\'s Medium E with 10% of fetal calf serum (FBS) and carefully overlaid on a 60% Percoll solution (1:1). The cell suspension was fractionated by centrifugation at 750g for 20 min, without break, at 20 °C. Viable hepatocytes deposited in the pellet were washed with Williams\'s Medium E with 10% FBS, spun at 50g for 3 min and resuspended in complete Williams\'s Medium E (supplemented with 4% FBS and 1% penicillin/streptomycin). Viability and yield were assessed by trypan blue staining. Viable hepatocytes were plated on collagen-coated 24-well plates.

RNAi {#S6}
----

HepG2 cells were reverse-transfected with target-specific SMARTpool siRNA pools, as previously described[@R36]. Non-targeting SMARTpool siRNA was used as a negative control (Dharmacon, GE Healthcare). The efficiency of knockdown was assessed 48 h after transfection by qRT-PCR using kits from Applied Biosystems. Gene expression levels were normalised against those of hypoxanthine guanine phosphoribosyltransferase (Hprt1). The primer pairs used for qRT-PCR reactions are listed in [Table S3](#SD2){ref-type="supplementary-material"}.

Parasite lines {#S7}
--------------

*Plasmodium berghei* sporozoites were obtained through dissection of the salivary glands of infected female *Anopheles stephensi* mosquitoes bred at the Instituto de Medicina Molecular. The following parasite lines were used: GFP-expressing *P. berghei* ANKA (259cl2, Leiden Malaria Research Group), *uis3(-)*[@R5], *uis3(+),* and *uis3-myc P. berghei* NK65 (generated for this study).

*Plasmodium* transfection {#S8}
-------------------------

*P. berghei uis3-myc* and *uis3(+)* were obtained by complementing the *uis3(-)* parasite line via single cross-over recombination as described in [Supplementary Fig. 2](#SD2){ref-type="supplementary-material"}. Transfection was done by electroporation of purified schizonts as previously described[@R37]. Parasites were selected with WR99210 (kindly provided by Jacobus Pharmaceuticals, Princeton, NJ, USA) for 4 consecutive days, harvested on day 10 post transfection, and genotyped by PCR with the primers listed in [Table S2](#SD2){ref-type="supplementary-material"}.

Infections {#S9}
----------

Hepatoma cells, MEFs, and mouse primary hepatocytes were plated on 24-well culture plates at a density of 65.000, 50.000, and 120.000 cells/well, respectively. Cells were infected with freshly dissected *P. berghei* sporozoites (30.000/well) 1 day after seeding and processed for analysis at 24 h or 48 h. siRNA-treated HepG2 cells were infected with *uis3(+)* or *uis3(-)* sporozoites 36 h after siRNA transfection and cultured for another 65 h in standard medium supplemented with 0.3 % Fungizone. At 65 h, the entire volume of cell culture medium (HepG2 SN) in each well was harvested and immediately inoculated into mice (1 well for each animal). The onset of blood stage parasitemia was monitored through Giemsa-stained thin blood smears by two unblinded independent observers. The smears were analysed daily from day 1 through day 10 after inoculation, when most animals suffered from hyperparasitemia and had to be sacrificed. On day 10, parasite genomic DNA was extracted from the blood of each experimental animal for parasite genotyping. The primer pairs used to probe the *uis3* wild-type and knockout genomic loci are listed in [Table S2](#SD2){ref-type="supplementary-material"}. For ROS scavenging experiments, Huh7 cells were incubated for 2 h in complete medium supplemented with 20 mM N-acetylcysteine (NAC), before sporozoite addition. Chloroquine (50 µM) was added to hepatoma cells 1 h after sporozoite infection.

Plasmids {#S10}
--------

Plasmids used in this study are listed in [Table S1](#SD2){ref-type="supplementary-material"}. All *Plasmodium* sequences (except single point mutants) and human LC3B were chemically synthesised and subcloned into pCMV-Myc-N or pCMV-HA-N expression vectors (Clontech) using the EcoRI and KpnI restriction sites (GeneArt, Invitrogen). The *Renilla* luciferase sequence was chemically synthesised (GeneArt, Invitrogen) and subcloned into pCMV-MYC-s*Pf*UIS3 using the EcoRI restriction site. Single point mutants of s*Pf*UIS3 were obtained by site-directed mutagenesis using the primers listed in [Table S4](#SD2){ref-type="supplementary-material"} and the QuickChange II site-directed mutagenesis kit (Agilent Technologies), following the manufacturer's instructions. For production of His6-s*Pf*UIS3 (WT and mutants), the soluble domain of *P. falciparum* UIS3 was amplified from pCMV-MYC-s*Pf*UIS3 (forward primer: 5'CATGGGATCCATGGAGCAGAAGCTG3'; reverse primer: 5'CCGCGGTCTCGAGTCAGTTCTCTTCCT3) and cloned into pET28a (Novagen). All plasmids were verified by sequencing. *Plasmodium* sequences were optimised for expression in mammalian cells.

Immunofluorescence {#S11}
------------------

Cells plated on glass coverslips were fixed in 4% paraformaldehyde (ChemCruz) for 10 min at room temperature (RT) and permeabilised/blocked with a solution of 0,2% saponin-1% BSA. For immunostaining, samples were incubated with primary antibodies diluted in blocking solution (2 h, RT), washed with PBS, incubated for 1 h at RT with AlexaFluor-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories) and Hoechst 33342 (Invitrogen), and washed again. The coverslips were then mounted on microscope slides with Fluoromount (SouthernBiotech). The following primary antibodies were used for confocal microscopy: LC3 (mouse monoclonal, MBL, M152-3), c-Myc (mouse monoclonal, MBL, M192-3), *Pb*HSP70 (2E6[@R38]), *Pb*UIS4[@R29] (goat polyclonal, SicGen, AB0042-200), LAMP1 (rabbit polyclonal, Sigma, L1418), and *Pb*MSP1[@R29] (rabbit polyclonal, GenScript, custom-made). All images were acquired on Zeiss confocal microscopes (LSM 510 META or LSM 710) and processed in ImageJ. For co-localisation analysis, the region of interest (ROI) corresponding to the PVM was defined by thresholding the UIS4 signal, after which the Manders coefficients M1 and M2 within the ROI were calculated using the Colocalisation Threshold plugin from ImageJ. For infection quantification by microscopy, parasites were detected with anti-*Pb*HSP70 (2E6) and anti-*Pb*MSP1 and imaged on a Zeiss Axiovert 200M wide-field microscope equipped with an automated stage. All images (42 per coverslip) were processed and analysed using ImageJ.

Immuno-EM {#S12}
---------

Huh7 cells were fixed 24 h after infection with 4% paraformaldehyde - 0.05% glutaraldehyde in 100 mM piperazine-N,N\[prime\]-bis(2-ethanesulfonic acid) (PIPES)-0.5 mM MgCl2 (pH 7.2) for 1 h at 4°C and processed as described previously[@R39]. Sections were stained with antibodies against human LC3 (mouse monoclonal, MBL, M152-3) and UIS4 (goat polyclonal, SicGen, AB0042-200), followed by gold-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories), and viewed on a JEOL 1200 EX transmission electron microscope (JEOL).

Molecular Docking of UIS3-LC3 complexes {#S13}
---------------------------------------

Homology models of the UIS3 soluble domains belonging to different Plasmodium species and human LC3 were built with the Phyre2 server (<http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index>) using the crystal structures of P. falciparum UIS3 (PDB code: 2VWA) and LC3B (PDB code: 2ZJD) as reference models. The quality of the homology models obtained was improved by atomic coordinate refinement using a two-step atomic-level energy refinement protocol implemented in ModRefiner software[@R40]. Experimental and homology-derived protein coordinates were then used to construct models of the human and mouse UIS3-LC3 complexes by flexible molecular docking with the Swarmdock algorithm[@R41]. LC3 proteins were considered as receptors and UIS3 as ligands. For each complex, an initial set of 100 ligand starting positions was generated in the space around the receptor, being further optimized by energy minimization. The top 10 docking solutions were ranked by increasing free energy, and submitted to an additional energy minimization cycle by conjugated gradient during 1000 steps with GROMACS[@R42], in order to avoid potential steric clashes between contact atoms. Visual inspection and cross comparison between the docking results obtained for the human and mouse complex showed a conserved pattern of molecular orientations for the top 5 docking solutions. Consensus residues involved in UIS3-LC3 interactions in the best docking solution were determined using CONS-COCOMAPS application[@R43] and graphically represented with the LigPlot+ software[@R44].

Co-Immunoprecipitation {#S14}
----------------------

HeLa cells expressing GFP-LC3 were transfected with plasmids encoding c-Myc or HA fusion proteins ([Table S1](#SD2){ref-type="supplementary-material"}) on 10 cm dishes and harvested 48 h after transfection in lysis buffer - 0.5 % NP-40, 150 mM NaCl, 10 mM Tris-Cl pH 7.4, 0.5 mM EDTA, supplemented with Complete protease inhibitor and PhosStop phosphatase inhibitor cocktails (Roche). On some experiments, HeLa cells were co-transfected with both myc-UIS3 and HA-tagged LC3. c-Myc- and HA-tagged proteins were purified from total cell lysates using the c-Myc tagged protein mild purification kit and the HA tagged protein purification kit, respectively, according to the manufacturer's instructions (MBL). GFP-LC3 was immunoprecipitated from total cell lysates using GFP-Trap® coupled to agarose beads (Chromotek). For immunoprecipitation of parasite-encoded UIS3-myc from infected cells, HeLa cells or mouse primary hepatocytes were lysed 24 h after infection with *uis3-myc P. berghei* and total cell lysates were processed as described above. Co-immunoprecipitated proteins and total cell lysates were analysed by Western blot using antibodies against LC3 (rabbit polyclonal, MBL, PM036), and c-Myc (mouse monoclonal, MBL, M192-3) or HA tags (mouse monoclonal, Biolegend, 901503) to detect UIS3 or UIS4, followed by HRP-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories). Immunoblots were developed using Luminata Crescendo Western HRP substrate reagent (Merck Millipore).

Expression and purification of recombinant proteins {#S15}
---------------------------------------------------

*Escherichia coli* (*E. coli*) BL21 cells were transformed with GST-His-tagged LC3 or GST-His bacterial expression vectors. After overnight culture in LB, cells were diluted 1/100 in fresh medium to an OD \~ 0.7 and incubated with 0.3 mM IPTG for 5 h to induce the expression of the recombinant proteins. All cultures were performed at 37°C with vigorous shaking. For expression of His-tagged s*Pf*UIS3^WT^, *E. coli* BL21 C43 bacteria were used. Cells grown overnight in LB were diluted 1/100 in fresh medium to an OD \~1.2. Recombinant protein expression was induced by the addition 0.3 mM IPTG and overnight culture at 25 °C. His-tagged s*Pf*UIS3 mutants were expressed in *E. coli* BL21 bacteria. Overnight cell cultures were diluted 1/100 in LB supplemented with NZY auto-induction reagent (NZYTech). Recombinant His-tagged proteins were initially purified by metal chelating affinity chromatography using His-Trap Ni-containing columns (GE Healthcare) connected to an AKTA Explorer chromatographic system (GE Healthcare). The His-trap column (1 mL bed volume) was equilibrated with sodium phosphate buffer pH 6.8 containing 1 M NaCl and 25 mM imidazole before protein injection. His-tagged proteins were eluted by a linear gradient of imidazole from 25-500 mM in the same phosphate buffer. Fractions containing protein were collected and pooled, and further polished by size exclusion chromatography purification using a Sephadex S-200 column (GE Healthcare) eluted with PBS. Fractions containing protein were analysed by SDS-PAGE, concentrated by ultrafiltration and stored at -80°C in PBS buffer containing 15% glycerol.

Interaction between recombinant proteins {#S16}
----------------------------------------

Recombinant s*Pf*UIS3 (5 µg) was incubated with recombinant GST-His6-LC3 (10 µg) or with GST-His6 (5 µg), pre-adsorbed to glutathione beads in lysis buffer (150 mM NaCl, 20 mM Tris--HCl (pH 7.4), 0.1% Triton-X100, 5% glycerol, 5 mM EDTA and Complete protease inhibitors (Roche)). After washing, the complex was eluted in lysis buffer supplemented with 10 mM reduced L-glutathione (Sigma-Aldrich) and analysed by western-blot with antibodies against LC3 (rabbit polyclonal, MBL, PM036) and c-Myc (mouse monoclonal, MBL, M192-3).

Surface plasmon resonance {#S17}
-------------------------

Recombinant s*Pf*UIS3 was immobilized on a Biacore CM5 chip surface following standard protocols provided by the manufacturer (GE-Healthcare). In brief, recombinant s*Pf*UIS3 was chemically immobilized via amine coupling to the free carboxyl groups on the CM5 chip through standard NHS/EDC procedures. Recombinant GST-His-LC3 dissolved in PBS buffer was injected over the immobilized s*Pf*UIS3 at various concentrations to generate affinity sensorgrams that were collected in a single-cycle mode with no regeneration between sample injections. Unspecific binding was monitored by injecting recombinant GST-His protein over the s*Pf*UIS3-coated chip under the same conditions. Normalized response sensorgrams were calculated by subtracting the unspecific binding contribution of the same molar concentrations of GST protein alone. All biosensor data processing and analysis and *K*~D~ calculation were performed using the Biacore T100 Evaluation Software (GE Healthcare version 2.01). For *K*~D~ calculation, a monovalent interaction model was assumed, with both proteins interacting with 1:1 stoichiometry.

Circular Dichroism {#S18}
------------------

Recombinant His-tagged s*Pf*UIS3 proteins (wild type and mutants) used for Circular Dichroism were purified using a modification of the already described protocol, where the elution buffer of the size exclusion chromatography was substituted by 50 mM sodium phosphate, 200 mM NaF, pH 7.5. CD spectra of s*Pf*UIS3 variants were collected between 190 and 260 nm in a JASCO J-815 spectropolarimeter (Tokyo, Japan) using 1 mm quartz cells from Hellma Analytics (Müllheim, Germany). Experiments were performed at 25° C. Each CD spectrum corresponds to the average of 10 technical replicates, corrected for the buffer background contribution. Mean molar residue ellipticity values, \[θ\], were determined through the following relationship[@R45]: $$\lbrack\theta\rbrack = \frac{\theta}{Nlc}$$ where θ is the observed ellipticity, *N* is the number of amino acid residues in each protein, *l* is the quartz cell optical path length and *c* is the protein molar concentration.

Autophagy induction and p62 degradation assay {#S19}
---------------------------------------------

HeLa cells were changed from normal growth medium to EBSS to induce amino acid starvation-dependent autophagy. After 7 h, cells were harvested in Laemmli buffer and analysed by Western blot with antibodies against p62 (rabbit polyclonal, Sigma-Aldrich, P0067) and gamma-tubulin (mouse monoclonal, Sigma-Aldrich, T5326). The levels of p62 were measured by quantifying the ratio of p62 to tubulin signals with ImageJ.

LUMIER competition assay {#S20}
------------------------

HEK 293T cells transiently transfected with Luc-p62 or Luc-s*Pf*UIS3 expressing plasmids ([Table S1](#SD2){ref-type="supplementary-material"}) were lysed 24 h post-transfection in LUMIER lysis buffer (150 mM NaCl, 20 mM Tris--HCl (pH 7.4), 0.1% Triton-X100, 5% glycerol, 5 mM EDTA and Complete protease inhibitors (Roche))[@R25]. The *Renilla* luciferase activity associated with each cell lysate was assessed using the *Renilla* Luciferase Assay System (Promega). Equivalent saturating amounts of luciferase-tagged p62 or s*Pf*UIS3 cell lysates were incubated with recombinant GST-His6-LC3B (500 ng), pre-adsorbed to glutathione beads. After washing away unbound protein, the precipitates were incubated with increasing concentrations of synthetic p62 LIR peptide (SGGDDDWTHLSSK) for 1 h with rotation, followed by elution in lysis buffer supplemented with 10 mM reduced L-glutathione (Sigma-Aldrich). The *Renilla* luciferase activity associated with LC3 after elution was quantified as described above using Tecan's Infinite 200M multiplate reader. The expression of luciferase-tagged p62 or s*Pf*UIS3 was additionally detected with an anti-*Renilla* luciferase antibody (Abcam).

LUMIER/GFP assay {#S21}
----------------

HEK 293T cells transiently transfected with PLEKHM1-GFP[@R46] and co-transfected with empty plasmid, Luc-s*Pf*UIS3^WT^, or Luc-s*Pf*UIS3^Mut1^ ([Table S1](#SD2){ref-type="supplementary-material"}) were lysed 24 h post-transfection in LUMIER lysis buffer (150 mM NaCl, 20 mM Tris--HCl (pH 7.4), 0.1% Triton-X100, 5% glycerol, 5 mM EDTA and Complete protease inhibitors (Roche)). The cell lysates were incubated with recombinant GST-His6-LC3B (500 ng), pre-adsorbed to glutathione beads, for 2h at 4 °C, with rotation. After washing away unbound proteins, pulldowns were eluted in lysis buffer supplemented with 10 mM reduced L-glutathione. GFP (excitation 420 nm, emission 520 nm) and *Renilla* luciferase activity associated with LC3 in each experimental condition were quantified using Tecan's Infinite 200M multiplate reader.

Statistical analysis {#S22}
--------------------

Data are expressed as means + SEM. Statistically significant differences between two different groups were determined using non-parametric two-tailed-Mann-Whitney test, unpaired two-tailed *t* test, or two-way ANOVA, as indicated. *P* values \< 0.05 were considered statistically significant. Significances are represented in the figures as follows: n.s. *P* \> 0.05; \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001; \*\*\**P* \< 0.0001. All tests were carried out in GraphPad Prism. The experiments were not randomised. Sample sizes on mice experiments were chosen on the basis of historical data, no statistical methods were used to predetermine sample size.

Data availability {#S23}
-----------------

The authors declare that the data supporting the findings of this study are available within the paper and its [supplementary information](#SD2){ref-type="supplementary-material"}.
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![*Plasmodium* UIS3 protects liver-stage parasites from host autophagy.\
**a,** Timeline of HepG2 infection and cell supernatant (HepG2 SN) transfer into C57BL/6 mice. **b, c,** HepG2 cells treated with siRNAs to silence Atg5 or Rab7 expression and infected with *uis3(+)* or *uis3(-)* parasites were fixed 65 h after infection and immunostained with anti-MSP1 (red), anti-*Pb*Hsp70 (green), and Hoechst (blue). Scale bar, 10 μm. Differentiated progeny are shown surrounded by a ring of MSP1 (b). The numbers of EEFs were quantified by microscopy (c). The bars represent the mean + SEM of pooled replicates from two (Atg5, Rab7) to four (Control) independent experiments normalised to the control. **d,** Representative images of Giemsa-stained blood smears from C57BL/6 mice 10 days after receiving the indicated HepG2 SN. **e**, Onset of blood stage parasitemia following inoculation of C57BL/6 mice with the indicated HepG2 SN. Animals that received control *uis3(-)* HepG2 SN remained parasite free up to 30 days after inoculation. The data represents the % of mice (out of 5 to 10; two independent experiments) with positive blood smears. **f**, Genotype of blood stage parasites harvested 10 days after mice inoculation with the indicated HepG2 SN. Wild-type and knockout *uis3* genomic loci were amplified with specific primer sets. One representative mouse from each experimental group is shown. **g,** Control (*Atg3^+/+^*, *Atg5^+/+^*, *Atg7^+/+^*) and autophagy-deficient MEFs (*Atg3^-/-^*, *Atg5^-/-^*, and *Atg7^-/-^*) were infected with *uis3(+)* or *uis3(-)* parasites, fixed at 48 h, and labeled with anti-*Pb*Hsp70 and Hoechst. EEF numbers were quantified by microscopy and normalised to the *uis3(+)* control of each cell line. The bars represent the mean + SEM of five independent experiments. **h,** Huh7 cells treated with chloroquine (CQ) from 1 h to 24 h after infection with *uis3(+)* or *uis3(-)* parasites were immunostained with anti-*Pb*UIS4, anti-*Pb*Hsp70, and Hoechst. The numbers of EEFs were quantified by microscopy in three independent experiments. Statistical significance was assessed using non-parametric two-tailed Mann-Whitney test. n.s. *P* \> 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001; \*\*\*\**P* \< 0.0001.](emss-74403-f001){#F1}

![*Plasmodium* UIS3 binds to host LC3.\
**a**, Timeline of *in vitro* infection and analysis. **b,** Representative confocal images (two independent experiments) of Huh7 cells infected with *P. berghei* expressing UIS3-myc (*uis3-myc*). Cells were fixed 24 h (top) and 48 h (bottom) after infection and immunostained with anti-myc (white), anti-UIS4 (red), anti-LC3 (green), and Hoescht (blue). Scale bar, 10 μm. **c,** Representative IEM micrograph of the host-parasite interface in a Huh7 cell 24 h after infection with *P. berghei*. *Pb*UIS4 and host LC3 are shown labeled with 12 nm (arrowheads) and 18 nm (arrows) gold particles, respectively. The EEF cytosol is marked with an asterisk (\*). The *Pb*UIS4-positive structures correspond to the PVM and tubular-vesicular network (TVN) of the parasite. Scale bar, 200 nm. Seventeen randomly selected cells were analysed. **d**, Lysates of GFP-LC3 HeLa cells infected with *uis3-myc* or *uis3(-) P. berghei* were immunoprecipitated with anti-myc. Analysis of the precipitates was done by western-blot with anti-LC3 and anti-myc antibodies (top and middle panels). Total cell lysates (TCL) were immunoblotted with anti-LC3 (bottom panel). **e**, Purified GST or GST-LC3 were used as bait to pull-down recombinant His-tagged s*Pf*UIS3. Pull-down fractions were immunoblotted with anti-GST and anti-His antibodies. One of four independent experiments is shown (d, e). **f**, Binding of GST-LC3 to s*Pf*UIS3 immobilised on a sensor chip was analysed by surface plasmon resonance (SPR). The indicated concentrations of GST-LC3 were perfused over the s*Pf*UIS3-coated sensor. Normalized response sensorgrams were calculated by subtracting the unspecific binding contribution of the same molar concentrations of GST alone. **g**, SPR response units at equilibrium plotted as a function of LC3 concentration. The dissociation constant of the interaction, *K*~D~, is shown.](emss-74403-f002){#F2}

![Non-canonical binding of *Plasmodium* UIS3 to the LIR pocket of LC3.\
**a**-**d**, Representations of the putative complex between the soluble domain of UIS3 and LC3 obtained by molecular docking. The LC3 areas depicted in green and orange represent the two hydrophobic pockets responsible for the recognition of LIR motifs and overlap significantly with the surface recognised by UIS3 (see [Supplementary Fig. 5d, e](#SD2){ref-type="supplementary-material"}). All key interacting amino acids are highlighted in black (LC3) and red (UIS3). The *P. falciparum* (a, b) and *P. berghei* complexes (c, d) are shown. **e**, **f**, Lysates of GFP-LC3 HeLa cells expressing the indicated s*Pf*UIS3 (e) or s*Pb*UIS3 (f) myc-tagged proteins (amino acid substitutions shown on the left) were immunoprecipitated with anti-myc. Precipitates were analysed by western-blot with anti-LC3 (top panels) and anti-myc (middle panels). TCL were immunoblotted with anti-LC3 (bottom panels). **g**, Relative contribution of single amino acid substitutions (shown on the left) to the binding of luciferase-tagged s*Pf*UIS3 to recombinant GST-LC3. The inset shows the outline of the pulldown assay. The average + SEM of two independent experiments is shown. **h**, Circular dichroism spectra of s*Pf*UIS3 recombinant proteins (wild-type and the indicated mutants). Each spectrum is the average of 10 technical replicates, corrected for the buffer background. **i**, Immunoprecipitation of myc-tagged s*Pf*UIS3^WT^from HeLa cell lysates co-expressing the indicated HA-tagged LC3 proteins (amino acid substitutions shown on top). Precipitates were probed with anti-HA (top panel) and anti-myc (middle panel). The bottom panel shows the levels of LC3 in TLC. One representative immunoblot of at least three independent experiments is shown (e, f, i). Statistical significance was assessed using unpaired two-tailed *t* test. \**P* \< 0,05; \*\**P* \< 0.01; \*\*\*\**P* \< 0.0001.](emss-74403-f003){#F3}

![UIS3 acts as a *bona fide* autophagy inhibitor by competing with host LC3-interacting proteins for LC3 binding.\
**a**, Western-blot analysis of p62 levels in HeLa cells expressing the indicated s*Pb*UIS3 proteins and kept for 8 h in complete (control) or amino acid-depleted medium (aa starvation). Whole cell lysates were analysed by western-blot for p62, tubulin, and UIS3-myc. Immunoblots representative of five independent experiments are shown. **b**, The levels of p62 before and after aa starvation were calculated as the ratio of p62 to tubulin. The bars represent the mean + SEM of five independent experiments. **c**, Outline of LUMIER competition assay. The assay measures the amount of p62 LIR peptide necessary to displace luciferase-tagged p62 or s*Pf*UIS3 from their complexes with recombinant GST-LC3. The inset shows the input levels (detected with anti-*Renilla* luciferase) of luciferase-tagged p62 and s*Pf*UIS3 in one (of three) representative experiment. **d**, Binding of luciferase-tagged p62 or s*Pf*UIS3 to recombinant GST-LC3 in the presence of the indicated concentrations of p62 LIR. The mean + SEM of three independent experiments is shown. For the data points corresponding to 2 and 5 µM of p62 LIR, n = 2. **e**, Recombinant GST-LC3 was used to pulldown extracts of HEK 293T cells co-transfected with the indicated plasmids. The ratio of PLEKHM1 and s*Pf*UIS3 in the pulldown *versus* input was calculated from the GFP and luminescence signals of each fraction. The bottom panels show the levels of PLEKHM1 and UIS3 in the input extract. The bars represent the average + SEM of three independent experiments. Statistical significance was assessed using unpaired two-tailed *t* test (b, e) and two-way ANOVA (d): n.s. *P* \> 0.05; \*\*\**P* \< 0.001; \*\*\*\**P* \< 0.0001. **f**, Summary of the observed effects of *Plasmodium* UIS3 on host autophagy. Antiplasmodial autophagy depends on the LC3 conjugation machinery and on lysosome-associated Rab7, with unidentified LIR-motif proteins mediating one or several steps leading to lysosomal fusion. The C-terminus of UIS3 binds to the LIR-docking site on LC3, rendering the site inaccessible for autophagy-promoting interactions.](emss-74403-f004){#F4}
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